Lead Product(s) : Cytomegalovirus Immune Globulin [Human],Ganciclovir
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Approved
Sponsor : Kamada
Deal Size : $145.0 million
Deal Type : Acquisition
Details : Under the terms of the agreement, Kamada Inc., will be responsible for the commercialization of the CYTOGAM®, WINRHO®, HEPAGAM B®, and VARIZIG® in the U.S., including direct sales to wholesalers and local distributers.
Brand Name : Cytogam
Molecule Type : Large molecule
Upfront Cash : $95.0 million
November 22, 2021
Lead Product(s) : Cytomegalovirus Immune Globulin [Human],Ganciclovir
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Approved
Sponsor : Kamada
Deal Size : $145.0 million
Deal Type : Acquisition
LOOKING FOR A SUPPLIER?
Reset All
